dexamethasone + dactinomycin + doxorubicin + methotrexate + etoposide

This is a **combination chemotherapy regimen** consisting of five antineoplastic agents: dexamethasone (a synthetic glucocorticoid corticosteroid), dactinomycin (actinomycin D, an antitumor antibiotic), doxorubicin (an anthracycline antibiotic), methotrexate (an antifolate antimetabolite), and etoposide (a topoisomerase II inhibitor). It does not represent a standard named regimen or have a unique brand name. Each component acts by a different mechanism: - **Dexamethasone** modulates inflammatory and immune responses, and is often used adjunctively in oncology for antiemetic and anti-inflammatory effects, as well as for reducing chemotherapy-induced adverse events[17]. - **Dactinomycin** intercalates DNA and inhibits RNA synthesis, disrupting the proliferation of cancer cells[10]. - **Doxorubicin** intercalates with DNA, inhibits topoisomerase II, and generates free radicals leading to DNA damage and apoptosis[1][8]. - **Methotrexate** inhibits dihydrofolate reductase, preventing DNA synthesis and cell replication[20]. - **Etoposide** inhibits topoisomerase II, causing errors in DNA synthesis, cell cycle arrest, and apoptosis[16]. This exact five-drug combination is not commonly described as a single named regimen, but similar multi-agent regimens (often with some overlap) are used for various **high-risk malignancies**, aggressive lymphomas, and gestational trophoblastic neoplasia (GTT). Precise indications may include salvage therapy or advanced/refractory cases in various pediatric and adult cancers, notably where highly aggressive, multi-agent chemotherapy is required[4][18][21].